Published in J Clin Invest on January 17, 2012
Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathog (2015) 1.49
IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. PLoS One (2015) 1.40
Occult HBV infection. Semin Immunopathol (2012) 1.37
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (2015) 1.19
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther (2013) 1.10
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet (2013) 0.99
Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol (2013) 0.98
Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice. J Virol (2014) 0.98
Present and future therapies of hepatitis B: From discovery to cure. Hepatology (2015) 0.96
The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1. PLoS Pathog (2014) 0.96
NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci (2014) 0.95
Experimental models and therapeutic approaches for HBV. Semin Immunopathol (2012) 0.95
The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. J Virol (2015) 0.94
Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol (2015) 0.94
Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol (2016) 0.94
Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A (2014) 0.93
Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med (2015) 0.93
Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect (2014) 0.90
Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A (2015) 0.90
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B (2014) 0.89
Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol (2013) 0.89
Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One (2014) 0.88
Strategies to eliminate HBV infection. Future Virol (2014) 0.87
Animal models for the study of HCV. Curr Opin Virol (2015) 0.86
In vivo models of hepatitis B and C virus infection. FEBS Lett (2016) 0.85
Roles of microRNAs in the hepatitis B virus infection and related diseases. Viruses (2013) 0.85
A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. J Virol (2015) 0.84
Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World J Hepatol (2015) 0.83
IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway. Biomed Res Int (2015) 0.83
Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol (2015) 0.83
Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One (2015) 0.82
Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions. Pathogens (2014) 0.82
Determinants of hepatitis B and delta virus host tropism. Curr Opin Virol (2015) 0.82
Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS One (2016) 0.81
Requirement of CRTC1 coactivator for hepatitis B virus transcription. Nucleic Acids Res (2014) 0.81
Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett (2014) 0.81
Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. Antiviral Res (2015) 0.80
Construction of a novel liver-targeting fusion interferon by incorporation of a Plasmodium region I-plus peptide. Biomed Res Int (2014) 0.80
Control of Hepatitis B Virus by Cytokines. Viruses (2017) 0.80
Adenoviral delivery of recombinant hepatitis B virus expressing foreign antigenic epitopes for immunotherapy of persistent viral infection. J Virol (2013) 0.79
Modeling hepatitis B virus infection, immunopathology and therapy in mice. Antiviral Res (2015) 0.79
Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol (2014) 0.79
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS One (2017) 0.79
Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model. J Infect Dis (2013) 0.78
Clinical impact of hepatitis B and C virus envelope glycoproteins. World J Gastroenterol (2013) 0.78
Antihepatitis B virus activity of a protein-enriched fraction from housefly (Musca domestica) in a stable HBV-producing cell line. ScientificWorldJournal (2014) 0.78
Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol (2015) 0.78
Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. J Immunol Res (2017) 0.78
Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. Clin Infect Dis (2016) 0.77
Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro. PLoS One (2015) 0.77
The infection efficiency and replication ability of circularized HBV DNA optimized the linear HBV DNA in vitro and in vivo. Int J Mol Sci (2015) 0.77
The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection. Front Microbiol (2016) 0.77
Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes. J Virol (2015) 0.77
Restrictive influence of SAMHD1 on Hepatitis B Virus life cycle. Sci Rep (2016) 0.77
The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state. Sci Rep (2016) 0.77
Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest (2017) 0.76
Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep (2016) 0.76
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. J Gastroenterol (2016) 0.76
Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. Sci Rep (2016) 0.75
Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis (2015) 0.75
Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res (2016) 0.75
Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepat Mon (2016) 0.75
The evolving role of interferons in viral eradication strategies. J Virus Erad (2016) 0.75
Reduced Expression of DNA Damage Repair Genes High Mobility Group Box1 and Poly(ADP-ribose) Polymerase1 in Inactive Carriers of Hepatitis B Virus Infection-A Possible Stage of Viral Integration. J Clin Exp Hepatol (2013) 0.75
Eradication Strategies for Chronic Hepatitis B Infection. Clin Infect Dis (2016) 0.75
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. Mediators Inflamm (2016) 0.75
Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection. Virol J (2015) 0.75
High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo. BMC Biotechnol (2015) 0.75
Genome-wide identification of direct HBx genomic targets. BMC Genomics (2017) 0.75
Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog (2017) 0.75
Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrence. Br J Cancer (2016) 0.75
MicroRNA-939 restricts Hepatitis B virus by targeting Jmjd3-mediated and C/EBPα-coordinated chromatin remodeling. Sci Rep (2016) 0.75
Treatment of hepatitis B virus: an update. Future Microbiol (2016) 0.75
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver (2017) 0.75
Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel) (2017) 0.75
Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B. Hepatology (2017) 0.75
An effective anti-viral approach targeting hepatitis B virus using NJK14047, a novel and selective biphenyl amide p38 MAPK inhibitor. Antimicrob Agents Chemother (2017) 0.75
Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods (2007) 45.04
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev (2004) 6.20
Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell (2010) 2.89
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
Hepatitis B viruses: reverse transcription a different way. Virus Res (2008) 2.06
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology (2007) 1.75
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol (2011) 1.70
Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology (2008) 1.68
Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol (2003) 1.39
Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A (2003) 1.35
Interferon inhibits hepatitis B virus replication in a stable expression system of transfected viral DNA. J Virol (1989) 1.30
p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene (2008) 1.19
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology (2011) 1.17
Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. J Virol (1990) 1.15
Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol (1999) 1.13
Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol (2010) 1.04
Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol (2009) 1.03
Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells. J Infect Dis (1992) 0.99
Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem (2011) 0.98
Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res (2002) 0.93
Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther (2008) 0.87
Integrated hepatitis B virus DNA preserves the binding sequence of transcription factor Yin and Yang 1 at the virus-cell junction. J Virol (2000) 0.83
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol (2004) 3.70
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology (2014) 2.39
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol (2002) 2.26
Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol (2003) 2.24
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology (2006) 2.05
Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology (2012) 1.92
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology (2007) 1.75
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol (2011) 1.70
RGB marking facilitates multicolor clonal cell tracking. Nat Med (2011) 1.69
Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology (2008) 1.68
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Partial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors. J Hepatol (2005) 1.54
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int (2010) 1.51
Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol (2013) 1.50
The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermatol (2004) 1.48
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
Occult HBV infection. Semin Immunopathol (2012) 1.37
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer (2006) 1.33
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 1.31
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol (2012) 1.29
Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis (2013) 1.25
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem (2006) 1.22
Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol (2002) 1.20
Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology (2011) 1.17
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008) 1.16
Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology (2012) 1.15
Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology (2010) 1.14
The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene (2002) 1.13
Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol (2002) 1.10
Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol (2005) 1.09
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology (2002) 1.07
hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol (2009) 1.06
p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Cancer Res (2009) 1.05
DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene (2002) 1.04
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Dig Liver Dis (2011) 1.03
Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis (2011) 1.03
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (2014) 1.02
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis (2013) 1.02
What is the clinical impact of occult hepatitis B virus infection? Lancet (2005) 1.01
Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur J Immunol (2002) 1.01
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res (2009) 1.01
Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol (2010) 1.01
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther (2012) 1.01
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica (2011) 1.00
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood (2006) 0.99